<DOC>
	<DOC>NCT02316821</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of RTA 402 in chronic kidney disease (CKD) patients with type 2 diabetes in a double-blind, placebo-controlled study when this compound is administered once daily for 16 weeks in an intrapatient dose escalation design.</brief_summary>
	<brief_title>The Phase II Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes; TSUBAKI Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>CKD patients with type 2 diabetes mellitus Patients whose estimated GFR levels are eligible for this study Patients being treated with stable dose of angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II receptor blocker (ARB) etc. Patients with type 1 diabetes mellitus Patients with known nondiabetic renal disease Patients with a history of renal transplantation Patients with mean systolic blood pressure &gt; 160 mmHg or diastolic blood pressure &gt; 90 mmHg Patients with Hemoglobin A1c &gt; 10% Patients with cardiovascular disease specified in the study protocol etc.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>Diabetic Nephropathies</keyword>
	<keyword>Kidney Diseases</keyword>
	<keyword>Renal Insufficiency, Chronic</keyword>
	<keyword>Diabetes Complications</keyword>
	<keyword>Endocrine System Diseases</keyword>
	<keyword>Glucose Metabolism Disorders</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Renal Insufficiency</keyword>
	<keyword>Urologic Diseases</keyword>
	<keyword>bardoxolone methyl</keyword>
</DOC>